Monte Rosa Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
GLUE Nasdaq 8731 https://www.monterosatx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Monte Rosa Therapeutics Inc

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why - Apr 10th, 2024 12:50 pm
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect? - Apr 4th, 2024 1:55 pm
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why - Mar 22nd, 2024 12:50 pm
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know - Mar 19th, 2024 1:55 pm
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results - Mar 16th, 2024 9:31 am
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? - Mar 15th, 2024 11:09 am
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Mar 14th, 2024 11:00 am
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor - Mar 11th, 2024 11:00 am
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Jan 31st, 2024 12:00 pm
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street - Jan 16th, 2024 2:00 pm
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 - Jan 8th, 2024 12:15 pm
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2024 12:00 pm
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference - Nov 21st, 2023 12:00 pm
Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developments - Nov 9th, 2023 1:10 pm
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Nov 9th, 2023 12:00 pm
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases - Nov 7th, 2023 3:00 pm
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules - Oct 26th, 2023 8:30 pm
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE) - Oct 24th, 2023 1:35 pm
Roche is stuck on molecular glue - Oct 17th, 2023 12:03 pm
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases - Oct 17th, 2023 11:00 am